OBSERVATION {#s0}
===========

Antimicrobial resistance is a major public health threat worldwide, leading to an estimated 23,000 deaths annually in the United States alone ([@B1]). Carbapenem-resistant Gram-negative bacteria are particularly concerning as they typically display multidrug-resistance and are associated with higher mortality rates ([@B2]). Carbapenem-resistant *Enterobacteriaceae* (CRE) can possess a variety of antimicrobial resistance mechanisms, both intrinsic and acquired, that render antimicrobials ineffective. Among these mechanisms, acquired carbapenemases, such as Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM), are of greatest public health concern because of the potential for rapid dissemination of genes encoding these enzymes via mobile genetic elements, including plasmids and integrons ([@B3]).

Carbapenem resistance spurred the development of new antibiotics and combination drugs, including plazomicin, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam ([@B4]) while also renewing use of older agents, such as colistin ([@B5]). However, resistance to these drugs also exists, as new beta-lactamase inhibitors (avibactam, vaborbactam, relebactam) do not inhibit metallo-beta-lactamases ([@B4]), plazomicin is inactivated by 16S rRNA methyltransferases ([@B4]), and mobile colistin resistance (*mcr*) has also been reported ([@B6]).

In August 2016, a female patient in her 70s in Nevada who had recently arrived from India was admitted to an acute care hospital with a diagnosis of systemic inflammatory response syndrome ([@B7]). In the 2 years preceding her U.S. hospitalization, the patient received health care multiple times in India for a right femur fracture and subsequent complications. Blood cultures during her last hospitalization were negative; however, a right lateral hip abscess culture revealed monomicrobial growth of Klebsiella pneumoniae that was nonsusceptible to all antimicrobial drugs tested. The patient developed septic shock in September 2016 and died with the CRE. Here, we report the genome sequence and genomic analysis of this isolate and elucidate contributing mechanisms leading to the observed phenotypic profile.

A K. pneumoniae strain was isolated from a hip abscess culture, and antimicrobial susceptibility testing was performed and interpreted using CLSI reference broth microdilution (M100, M07) ([Table 1](#tab1){ref-type="table"}). The MIC for fosfomycin was determined by Etest (BioMérieux; Durham, NC) and the CLSI reference agar dilution using Mueller-Hinton agar II (BBL) with 25 µg/ml glucose 6-phosphate sodium salt (M100, M07). MICs of tigecycline and ceftazidime-avibactam were interpreted according to breakpoints established by the U.S. Food and Drug Administration (FDA; Silver Springs, MD). DNA was extracted according to methods previously described ([@B8]), and whole-genome sequencing data were generated using short-read (Illumina, San Diego, CA) and long-read (Pacific Biosciences, Menlo Park, CA) technology. PacBio long reads were assembled *de novo* using HGAP V3 and were subsequently polished with Quiver ([@B9]). Illumina short reads were then mapped to the polished long-read contigs for minor error correction using Pilon 1.21 ([@B10]). Acquired antimicrobial resistance genes were identified on high-quality contigs using the Resfinder repository ([@B11]) and SSTAR V1.1.01 ([@B12]). Finally, additional genes were detected with PGAP ([@B13]) and ISfinder ([@B14]) to identify genes contributing to displayed phenotypic resistance which could not be explained by acquired mechanisms present in the Resfinder collection alone.

###### 

Antimicrobial susceptibility testing results using broth microdilution, agar dilution, and Etest[^a^](#ngtab1.1){ref-type="table-fn"}

  Class and antimicrobial(s)                                       MIC(s) (μg/ml)                                                                     Interpretation   Associated resistance gene(s)
  ---------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------- ---------------------------------------------------------------
  Aminoglycoside                                                                                                                                                       
      Amikacin                                                     \>64                                                                               R                *aacA4*, *rmtC*
      Gentamicin                                                   \>16                                                                               R                *aacA4*, *rmtC*
      Tobramycin                                                   \>16                                                                               R                *aacA4*, *rmtC*
  Beta-lactam                                                                                                                                                          
      Ampicillin                                                   \>32                                                                               R                *bla*~CTX-M-15~, *bla*~SHV-28~, *bla*~CMY-6~, *bla*~NDM-1~
      Aztreonam                                                    \>64                                                                               R                *bla*~CTX-M-15~, *bla*~CMY-6~
      Cefazolin                                                    \>8                                                                                R                *bla*~CTX-M-15~, *bla*~SHV-28~, *bla*~CMY-6~, *bla*~NDM-1~
      Cefepime                                                     \>32                                                                               R                *bla*~CTX-M-15~, *bla*~NDM-1~
      Cefotaxime                                                   \>64                                                                               R                *bla*~CTX-M-15~, *bla*~CMY-6~, *bla*~NDM-1~
      Cefotaxime-clavulanic acid                                   \>32/4                                                                             ND               *bla*~CMY-6~, *bla*~NDM-1~
      Cefoxitin                                                    \>16                                                                               R                *bla*~CMY-6~, *bla*~NDM-1~
      Ceftazidime                                                  \>128                                                                              R                *bla*~CTX-M-15~, *bla*~CMY-6~, *bla*~NDM-1~
      Ceftazidime-avibactam[^b^](#ngtab1.2){ref-type="table-fn"}   \>16/4                                                                             R                *bla*~NDM-1~
      Ceftazidime-clavulanic acid                                  \>64/4                                                                             ND               *bla*~CMY-6~, *bla*~NDM-1~
      Ceftriaxone                                                  \>32                                                                               R                *bla*~CTX-M-15~, *bla*~CMY-6~, *bla*~NDM-1~
      Doripenem                                                    \>8                                                                                R                *bla*~NDM-1~
      Ertapenem                                                    \>8                                                                                R                *bla*~NDM-1~
      Imipenem                                                     32                                                                                 R                *bla*~NDM-1~
      Meropenem                                                    \>8                                                                                R                *bla*~NDM-1~
      Piperacillin-tazobactam                                      \>128/4                                                                            R                *bla*~NDM-1~
  Chloramphenicol                                                                                                                                                      
      Chloramphenicol                                              \>16                                                                               R                Truncated *ramR*
  Fluoroquinolone                                                                                                                                                      
      Ciprofloxacin                                                \>8                                                                                R                *oqxA*, *oqxB*, *gyrA* and *parC* mutations, truncated *ramR*
      Levofloxacin                                                 \>8                                                                                R                *oqxA*, *oqxB*, *gyrA* and *parC* mutations, truncated *ramR*
  Fosfomycin                                                                                                                                                           
      Fosfomycin                                                   32[^c^](#ngtab1.3){ref-type="table-fn"}, 16[^d^](#ngtab1.4){ref-type="table-fn"}   ND               *fosA*
  Polymyxin                                                                                                                                                            
      Colistin                                                     \>8                                                                                NWT              Disrupted *mgrB*
      Polymyxin-B                                                  \>8                                                                                NWT              Disrupted *mgrB*
  Sulfonamide                                                                                                                                                          
      Trimethoprim-sulfamethoxazole                                8/152                                                                              R                *sul1*
  Tetracycline                                                                                                                                                         
      Tetracycline                                                 \>32                                                                               R                *tet*(A), truncated *ramR*
      Tigecycline[^b^](#ngtab1.2){ref-type="table-fn"}             4                                                                                  I                Truncated *ramR*
  Macrolide                                                                                                                                                            
      Not included in AST panel                                    Na                                                                                 Na               *mph*(A)

Interpretations were based on CLSI guidelines or FDA breakpoints. Cellular location for resistance genes *bla*~CMY-6~, *bla*~NDM-1~, *aacA4*, *rmtC*, and *sul1* was plasmid IncA/C2; cellular location for resistance genes *mph*(A) and *tet*(A) was plasmid IncFIB(K). The cellular location for resistance genes *bla*~CTX-M-15~, *bla*~SHV-28~, *fosA*, *oqxA*, *oqxB*, *mgrB*, *ramR*, *gyrA*, and *parC* was chromosomal. R, resistant; I, intermediate; ND, not defined; NWT, non-wild type; Na, not applicable.

FDA breakpoints.
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The sequenced K. pneumoniae isolate contained a 5.8-Mb genome, including a 5.4-Mb chromosome and three plasmids, and belonged to multilocus sequence typing (MLST) strain 15 (ST15). K. pneumoniae ST15 has spread globally and is responsible for the high prevalence of CTX-M-15 in Asia and Europe ([@B15]). This sequence type often displays resistance to beta-lactams and fluoroquinolones and was recently associated with transferable *mcr-1* colistin resistance ([@B16]). Our isolate harbored three different plasmids of incompatibility groups A/C2, FIB(pKPHS1), and FIB(K).

Details for mechanisms of resistance are described in [Table 1](#tab1){ref-type="table"}. The conjugative IncA/C2 plasmid carried *bla*~NDM-1~ carbapenemase and *bla*~CMY-6~ class C beta-lactamase genes, both of which are commonly inserted into broad-host-range plasmids, such as IncA/C2 ([@B17]). In addition to plasmid-mediated beta-lactamase genes, we identified two chromosomally located beta-lactamase genes, *bla*~CTX-M-15~ and *bla*~SHV-28~. The extended-spectrum-beta-lactamase (ESBL) *bla*~CTX-M-15~ gene likely inserted itself into the chromosome via an ISEc9 (also called ISEcp1) insertion sequence ([Fig. 1A](#fig1){ref-type="fig"}), a previously described resistance gene mobile element association ([@B18]). The presence of these four beta-lactamases accounted for all displayed phenotypic resistance to beta-lactams, including the new combination drug ceftazidime-avibactam ([Table 1](#tab1){ref-type="table"}). Also of note, this K. pneumoniae isolate would likely be resistant to the newer agents meropenem-vaborbactam and imipenem-relebactam. Although not tested, the beta-lactamase inhibitors in these agents do not inactivate metallo-beta-lactamases, such as NDM. Carbapenem resistance can also originate from intrinsic mechanisms due to mutations in outer membrane porins (OMPs). Although we identified a previously described OmpK36 variant that is associated with carbapenem nonsusceptibility likely resulting from reduced outer membrane permeability (GenBank accession number [ACM07443](https://www.ncbi.nlm.nih.gov/protein/ACM07443)) ([@B19]), we did not observe any premature stop codons leading to truncations in OmpK35, OmpK36, or OmpK37 previously associated with reduced outer membrane permeability.

![(A) Chromosomal integration of *bla*~CTX-M-15~ by an ISEc9 insertion sequence. The *bla*~CTX-M-15~ gene is highlighted in red, mobile elements are peach, and all other genes are blue. Numbers indicate chromosomal locations. (B) The nonconjugative IncFIB(pKPHS1) p1605752FIB_2 plasmid carried by our isolate (I) was highly similar to a plasmid previously isolated in Nepal from K. pneumoniae strain ST15 (II). Gray areas indicate regions of similarity; white areas represent nonhomologous regions. No known antimicrobial resistance genes were present on either plasmid. (C) Conjugative IncA/C2 p1605752AC2 plasmid of our isolate (II) compared to the two most closely related IncA/C2 plasmids, pNDM-KN (I) and pNDM-US (III). Gray areas indicate regions of similarity; white areas represent nonhomologous regions. Known antimicrobial resistance genes are indicated with colored arrows.](mbo0021838070001){#fig1}

Although transferable *mcr* has been documented in ST15 strains, this isolate did not harbor any *mcr* genes. Colistin resistance was likely explained by the insertional inactivation of the *mgrB* regulator gene by an IS1 element ([@B20])**.** The MgrB protein acts as a negative-feedback regulator controlling the PhoP/PhoQ signaling system. Upregulation of this system due to *mgrB* inactivation activates the lipopolysaccharide modification system of the cell, which subsequently leads to polymyxin resistance ([@B20]). No amino acid changes in either PhoP/PhoQ or PmrA/PmrB, previously associated with intrinsic resistance to colistin, were identified.

Using K. pneumoniae strain ATCC 43816 as a reference, mutations leading to amino acid changes that render fluoroquinolones inactive were identified in two chromosomal genes, *gyrA* (S83F and D87A) and *parC* (S80I) ([@B21]). We also identified a frameshift mutation resulting in internal stop codons in the *ramR* transcriptional repressor gene which likely rendered it nonfunctional, leading to overexpression of the AcrAB efflux pump and to resistance to tigecycline ([@B22]), tetracycline, fluoroquinolones, and chloramphenicol ([@B23]).

To further confirm efflux pump contributions to the displayed MIC values, an efflux inhibitor assay was performed, as previously described ([@B24]). Antibiotic susceptibility testing was performed with and without 43.75 µg/ml of PAβN, a known efflux pump inhibitor. MIC values were lower in the presence of PAβN for chloramphenicol (4 μg/ml versus \>16 μg/ml), minocycline (\<4 μg/ml versus \>16 μg/ml), and tigecycline (2 μg/ml versus 4 μg/ml). MIC values for both fluoroquinolones tested did not differ in the presence or absence of PAβN, likely due to mutations in *gyrA* and *parC*.

Although the isolate harbored a *fosA* gene and susceptibility testing was performed, currently, no CLSI MIC breakpoints exist for fosfomycin susceptibility in K. pneumoniae. Finally, we identified one gene, *mph*(A), which confers resistance to macrolides and has the potential to spread due to its location on a plasmid. However, phenotypic resistance was not documented, as macrolides are not included in our antimicrobial susceptibility test panel.

To estimate the origin of our isolate, we screened the whole-genome sequence against publicly available K. pneumoniae isolates in the genome database at NCBI (*n* = 2,919) using a combination of the Genome Tree Report (<https://www.ncbi.nlm.nih.gov/genome/tree>) and LYVE-SET 1.1.4f (<https://github.com/lskatz/lyve-SET>). Our isolate grouped with 140 K. pneumoniae isolates with a single nucleotide polymorphism (SNP) range of 89 to 3,248, and the cluster was dominated by isolates from Europe, South Asia, and the United States ([Fig. 2](#fig2){ref-type="fig"}). Our isolate was most closely related to NDM-producing ST15 K. pneumoniae MGH171 (GenBank accession number [NGTL00000000.1](https://www.ncbi.nlm.nih.gov/nuccore/NGTL00000000.1)) from Massachusetts General Hospital, Boston, MA, USA (89 SNPs over a 5.4-Mb core genome, or 93% of the genome). The *bla*~NDM~ gene identified on the MGH171 genome assembly was partial, possibly due to an assembly artifact, and was located on a contig that also harbored the IncA/C2 replicon gene and *bla*~CMY-6~, increasing the likelihood of the presence of a true plasmid-mediated NDM in MGH171. Additionally, *bla*~NDM~ presence was observed in 12 other K. pneumoniae ST15 isolates, and the phylogenetic cluster also included ST15 specimens harboring carbapenemase genes *bla*~KPC-1~ (*n* = 7), *bla*~OXA-48~ (*n* = 2), and *bla*~VIM-1~ (*n* = 1) ([Fig. 2](#fig2){ref-type="fig"}).

![Our isolate, DHQP1605752_NV, clustered with 140 publicly available Klebsiella pneumoniae genome sequences. Presence or absence of known carbapenamase genes is listed for all isolates.](mbo0021838070002){#fig2}

The nonconjugative IncFIB(pKPHS1) plasmid (p1605752FIB_2) carried by our isolate, 111,692 bp in length, was highly similar to a 111,693-bp plasmid previously isolated in Nepal from a K. pneumoniae ST15 strain ([@B25]) (100% query coverage, 99% sequence similarity) (GenBank accession number [CP008931](https://www.ncbi.nlm.nih.gov/nuccore/CP008931)) ([Fig. 1B](#fig1){ref-type="fig"}). This isolate (GenBank accession number GCA_000764615.1) was also part of the cluster of 140 K. pneumoniae isolates described above and differed from our isolate by 354 SNPs over a core genome of 5.2 Mb, or 89% of the genome.

The sequence of the conjugative IncA/C2 plasmid (p1605752AC2) carrying *bla*~NDM-1~ was 140,133 bp in size and was similar to 13 other publically available plasmid sequences ([\>]{.ul}98% BLAST query coverage, [\>]{.ul}99% sequence identity), including pNDM-US from a K. pneumoniae ST11 strain isolated in the United States from a patient with a history of travel in India (GenBank accession number [CP006661](https://www.ncbi.nlm.nih.gov/nuccore/CP006661)) and pNDM-KN from Kenya (GenBank accession number [JN157804](https://www.ncbi.nlm.nih.gov/nuccore/JN157804)) ([Fig. 1C](#fig1){ref-type="fig"}). Lastly, conjugative plasmid IncFIB(K) (p1605752FIB), which carried antimicrobial resistance genes *mph*(A) and *tet*(A), did not share close homology with any known plasmids.

We report the isolation and characterization of a K. pneumoniae ST15 strain that was nonsusceptible to all antimicrobials tested and that likely shares a common ancestor with 140 globally disseminated K. pneumoniae strains, which all have publicly available genome sequences. We detected resistance determinants to explain nonsusceptibility to all 26 antimicrobials tested. All identified determinants were described previously in other Gram-negative bacteria and included both intrinsic and acquired mechanisms.

Evaluation of multidrug-resistant organisms using advanced molecular detection, including whole-genome sequencing, is needed to better understand the origins, acquisition, and spectrum of antimicrobial resistance mechanisms and their combination within one bacterial host. In addition, sequencing provides a broader context regarding the potential mobility of resistance determinants. Consequently, the additional information provided by sequencing may aid in identifying predecessor genotypes that could evolve to pan-resistance and in determining their global dissemination to inform public health response and containment.

Accession number(s). {#s1}
--------------------

Raw sequencing reads, genome assemblies, and MIC data were placed under BioProject [PRJNA391323](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA391323). The chromosome, IncA/C2, IncFIB(pKPHS1), and IncFIB(K) genome sequences were deposited under GenBank accession numbers [CP022127](https://www.ncbi.nlm.nih.gov/nuccore/CP022127), [CP022126](https://www.ncbi.nlm.nih.gov/nuccore/CP022126), [CP022128](https://www.ncbi.nlm.nih.gov/nuccore/CP022128), and [CP022125](https://www.ncbi.nlm.nih.gov/nuccore/CP022125), respectively.
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